ALNYLAM PHARMACEUTICALS, INC. Cost of Revenue
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Cost of Revenue of $298.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $298.26M, a 110.00% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $267.72M, a 160.81% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $197.23M, a 140.58% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for the quarter ending 2025-06-30 was $142.03M, a 111.13% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2025 was $677.17M, a 120.93% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2024 was $306.51M, a 14.28% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2023 was $268.22M, a 91.35% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2022 was $140.17M, a 21.89% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $298.26M 10-Q · filed 2026-07-30 | $505.78M 10-Q · filed 2026-07-30 | ||||||
| 2025-12-31 | $267.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $464.95M derived: sum of 2 quarters · filed 2026-02-12 | $606.98M derived: sum of 3 quarters · filed 2026-07-30 | $677.17M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $197.23M 10-Q · filed 2025-10-30 | $339.26M derived: sum of 2 quarters · filed 2026-07-30 | $409.44M 10-Q · filed 2025-10-30 | $512.09M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $142.03M 10-Q · filed 2026-07-30 | $212.21M 10-Q · filed 2026-07-30 | $314.86M derived: sum of 3 quarters · filed 2026-07-30 | $396.84M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $70.18M 10-Q · filed 2025-05-01 | $172.83M derived: sum of 2 quarters · filed 2026-02-12 | $254.81M derived: sum of 3 quarters · filed 2026-02-12 | $322.08M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-12-31 | $102.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $184.63M derived: sum of 2 quarters · filed 2026-02-12 | $251.90M derived: sum of 3 quarters · filed 2026-02-12 | $306.51M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $81.98M 10-Q · filed 2025-10-30 | $149.25M derived: sum of 2 quarters · filed 2025-10-30 | $203.86M 10-Q · filed 2025-10-30 | $275.84M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $67.27M 10-Q · filed 2025-07-31 | $121.88M 10-Q · filed 2025-07-31 | $193.86M derived: sum of 3 quarters · filed 2026-02-12 | $273.33M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $54.61M 10-Q · filed 2025-05-01 | $126.59M derived: sum of 2 quarters · filed 2026-02-12 | $206.06M derived: sum of 3 quarters · filed 2026-02-12 | $281.40M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $71.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $151.45M derived: sum of 2 quarters · filed 2026-02-12 | $226.78M derived: sum of 3 quarters · filed 2026-02-12 | $268.22M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $79.47M 10-Q · filed 2024-10-31 | $154.81M derived: sum of 2 quarters · filed 2024-10-31 | $196.24M 10-Q · filed 2024-10-31 | $242.41M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $75.34M 10-Q · filed 2024-08-01 | $116.77M 10-Q · filed 2024-08-01 | $162.94M derived: sum of 3 quarters · filed 2025-02-13 | $199.45M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $41.43M 10-Q · filed 2024-05-02 | $87.60M derived: sum of 2 quarters · filed 2025-02-13 | $124.11M derived: sum of 3 quarters · filed 2025-02-13 | $158.15M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $46.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $82.68M derived: sum of 2 quarters · filed 2025-02-13 | $116.72M derived: sum of 3 quarters · filed 2025-02-13 | $140.17M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $36.51M 10-Q · filed 2023-11-02 | $70.55M derived: sum of 2 quarters · filed 2023-11-02 | $94.00M 10-Q · filed 2023-11-02 | $127.64M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $34.04M 10-Q · filed 2023-08-03 | $57.49M 10-Q · filed 2023-08-03 | $91.13M derived: sum of 3 quarters · filed 2024-02-15 | $119.22M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $23.46M 10-Q · filed 2023-05-04 | $57.09M derived: sum of 2 quarters · filed 2024-02-15 | $85.18M derived: sum of 3 quarters · filed 2024-02-15 | $115.44M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $33.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $61.73M derived: sum of 2 quarters · filed 2024-02-15 | $91.98M derived: sum of 3 quarters · filed 2024-02-15 | $115.00M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $28.09M 10-Q · filed 2022-10-27 | $58.35M derived: sum of 2 quarters · filed 2022-10-27 | $81.37M 10-Q · filed 2022-10-27 | $103.16M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $30.26M 10-Q · filed 2022-07-28 | $53.28M 10-Q · filed 2022-07-28 | $75.07M derived: sum of 3 quarters · filed 2023-02-23 | $95.90M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $23.02M 10-Q · filed 2022-04-28 | $44.81M derived: sum of 2 quarters · filed 2023-02-23 | $65.64M derived: sum of 3 quarters · filed 2023-02-23 | $83.91M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $21.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $42.62M derived: sum of 2 quarters · filed 2023-02-23 | $60.88M derived: sum of 3 quarters · filed 2023-02-23 | $74.19M 10-K · filed 2023-02-23 | $78.05M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $20.83M 10-Q · filed 2021-10-28 | $21.80M 10-Q · filed 2020-11-05 | $39.09M derived: sum of 2 quarters · filed 2021-10-28 | $52.39M 10-Q · filed 2021-10-28 | $55.03M 10-Q · filed 2020-11-05 | $64.57M derived: sum of 4 quarters · filed 2022-02-10 | ||
| 2020-06-30 | $18.27M 10-Q · filed 2021-08-03 | $19.93M 10-Q · filed 2020-08-06 | $31.57M 10-Q · filed 2021-08-03 | $33.23M 10-Q · filed 2020-08-06 | $43.74M derived: sum of 3 quarters · filed 2022-02-10 | $48.96M derived: sum of 4 quarters · filed 2022-02-10 | ||
| 2020-03-31 | $13.30M 10-Q · filed 2021-04-29 | $25.48M derived: sum of 2 quarters · filed 2022-02-10 | $30.69M derived: sum of 3 quarters · filed 2022-02-10 | $35.02M derived: sum of 4 quarters · filed 2022-02-10 | ||||
| 2019-12-31 | $12.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $17.39M derived: sum of 2 quarters · filed 2022-02-10 | $21.71M derived: sum of 3 quarters · filed 2022-02-10 | $25.06M 10-K · filed 2022-02-10 | ||||
| 2019-09-30 | $5.21M 10-Q · filed 2020-11-05 | $9.54M derived: sum of 2 quarters · filed 2020-11-05 | $12.89M 10-Q · filed 2020-11-05 | $14.55M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $4.33M 10-Q · filed 2020-08-06 | $7.67M 10-Q · filed 2020-08-06 | $9.34M derived: sum of 3 quarters · filed 2021-02-11 | $9.47M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $3.35M 10-Q · filed 2020-05-06 | $5.01M derived: sum of 2 quarters · filed 2021-02-11 | $5.15M derived: sum of 3 quarters · filed 2021-02-11 | |||||
| 2018-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $1.80M derived: sum of 2 quarters · filed 2021-02-11 | $1.80M 10-K · filed 2021-02-11 | |||||
| 2018-09-30 | $137.00K 10-Q · filed 2019-10-31 | $137.00K 10-Q · filed 2019-10-31 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |